首页> 外国专利> METHOD OF DETERMINING THE NECESSITY OF USING PSYCHO PHARMACOTHERAPY AMONG THE PATIENTS WITH DISORDERS OF AUTIST SPECTRUM AT THE MOMENT OF THEIR EXAMINATION

METHOD OF DETERMINING THE NECESSITY OF USING PSYCHO PHARMACOTHERAPY AMONG THE PATIENTS WITH DISORDERS OF AUTIST SPECTRUM AT THE MOMENT OF THEIR EXAMINATION

机译:在患者进行检查时确定自闭症患者是否患有精神分裂症的药物治疗的必要性的方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to psychiatry, and can be used in order to assess the need for psychopharmacotherapy of the patient with autism spectrum disorder (ASD). Method of the invention includes clinical examination of patients, determination of the nosological affiliation of the disease according to ICD-10 and DSM-5 and additionally the neurophysiological examination by means of determining the features of the bioelectrical activity of the patient's brain during electroencephalography, mainly within the range of beta and theta rhythms, and immunological examination of patients by means of determining the enzymatic activity of leukocyte elastase (LE) in the serum of peripheral blood, functional activity of the α1-proteinase inhibitor (α1-PI) and the level of autoantibodies (aAB) to neurospecific antigens – S-100b and to the main myelin protein (MMP). Psycho pharmacotherapy is prescribed to the patient based on the results of clinical examination at the significant excess of the additional studies indicators over the similar ones among healthy children of the corresponding age.;EFFECT: use of the invention allows to evaluate the activity of the current pathological process in the brain of patients with ASD at the time of examination and to determine the need for the drug therapy at the particular stage of the disease course.;1 cl, 2 ex, 2 tbl
机译:技术领域本发明涉及医学,即精神病学,并且可以用于评估自闭症谱系障碍(ASD)患者的心理药物疗法的需要。本发明的方法包括对患者进行临床检查,根据ICD-10和DSM-5确定疾病的疾病学归属,以及另外通过确定脑电图检查期间患者大脑的生物电活动特征来进行神经生理检查。通过确定外周血血清中白细胞弹性蛋白酶(LE)的酶促活性,α1-蛋白酶抑制剂(α1-P​​I)的功能活性和针对神经特异性抗原S-100b和主要髓磷脂蛋白(MMP)的自身抗体(aAB)。根据临床检查的结果,对患者开出了心理药物疗法,其额外的研究指标明显超过了相应年龄健康儿童中的相似研究指标。效果:本发明的使用允许评估当前药物的活性检查时患有ASD的患者的大脑病理过程,并确定在疾病过程的特定阶段是否需要药物治疗。; 1 cl,2 ex,2 tbl

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号